Now we are looking for 1120 on this. That will still give 40 PE. While ADSK likes got 100.
Criminal Goldman indicating that the end of Dot Com II is very near. This criminal is coming out and putting super high targets on every bubble stock, just like they always to so they can short high just before the market crash.
ISRG surgical robotics work but they are too expensive for most hospitals and require special training. A whole slew of robotic surgical devices are coming to market and many are approved and selling for a fraction of the cost.
I agree/ an entire new intelligence is coming/ in the end, I think this company will be antiquated, however, I can see this one going to $1000-$1100 first!
The shorts are getting eaten today...
Goldman is not playing pump and dump. Their reputation is at stake. They genuinely believe their statements because they are caught up in the "kan't lose" moment like everyone else. Even Buffett is going around telling everyone to get into stocks at these bubble levels. The real indicator for market timing is the Elliott wave count and it does not look great for ISRG going forward.
I was just looking at this stock 6 months ago. After 5 years of doing nothing, my look sends it 50% higher. Wow. Do I regret not buying? Not completely. The NVDA stock I bought instead has just doubled. 67-134. Still, I've always wanted to own this stock.
another secret in this field is mzor,just starting like isrg,look at this stock.
I think ISRG is due for a pullback. What are your thoughts? check out aw-esomeSTOCKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
Grinding up a cancer tumour by robotics is the quickest way to spread cancer throughout the blood stream.
Charts pointing to 870 on this baby
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)